Understanding the Regulatory Affairs Consulting Market in Pharma

CHALLENGE

A private equity firm sought to deepen their understanding of the regulatory affairs (RA) consulting services market within the pharmaceutical industry. They were particularly interested in exploring the decision-making process pharma companies use when selecting RA consulting services, the key criteria influencing these decisions, and identifying the major players in this space. The objective was to gather comprehensive insights that would inform their strategic planning and investment decisions.

BTHT APPROACH

To address our client's needs in the shortest time, our team conducted a targeted search for experts with significant experience and expertise in regulatory affairs. We curated a diverse portfolio of professionals from the pharmaceutical industry who have been directly involved in the selection and use of RA consulting services. The expert profiles included:

• A leading expert with former positions of Chief Technology Officer, Managing Director, and Vice President; specializing in development and regulatory strategy,
• Directors of Global Regulatory CMC with in-depth knowledge of global regulatory standards and practices.
• Former Health Policy Regulatory and Legislative Director who has worked closely with regulatory bodies and has a comprehensive understanding of health policy implications.

These experts provided valuable insights into the factors that influence the decision-making process for purchasing RA consulting services, such as the importance of specialized expertise, the need for global regulatory compliance, and the significance of cost-effectiveness. BTHT team facilitated the double blinded consultation to make sure all the necessary conditions were provided without any issue.

OUTCOME

The consultations provided our client with a nuanced understanding of the regulatory affairs consulting market. The insights gathered helped them comprehend the critical decision-making criteria used by pharma companies when selecting RA consultants, including the importance of a consultant's track record, their depth of expertise in specific therapeutic areas, and the cost-benefit considerations. Armed with this knowledge, the private equity firm was well-informed to make strategic decisions regarding potential investments and partnerships in the RA consulting sector.